News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Galmed Pharmaceuticals Release: Recently Published Independent Research Supports The Importance Of Reverse Cholesterol Transport On NASH Pathogenesis


6/4/2014 9:18:04 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TEL AVIV, Israel, June 4, 2014 (GLOBE NEWSWIRE) -- Galmed Pharmaceuticals Ltd. (Nasdaq:GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, announced today that recently published data in the April 2014 issue of Biochimie supports the importance of the regulation of ABCA1-induced reverse cholesterol transport on the pathogenesis of Non-Alcoholic Steato-Hepatitis, or NASH.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES